Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
Bader Alsaikhan, Khalid Alrabeeah, Serge CarrierMcGill University Health Centre, Montreal, Quebec, QC, CanadaAbstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studie...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-06-01
|
| Series: | International Journal of General Medicine |
| Online Access: | http://www.dovepress.com/management-options-for-the-treatment-of-benign-prostatic-hyperplasia-w-a17192 |
| Summary: | Bader Alsaikhan, Khalid Alrabeeah, Serge CarrierMcGill University Health Centre, Montreal, Quebec, QC, CanadaAbstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.Keywords: lower urinary tract symptoms, phosphodiesterase-5 inhibitors |
|---|---|
| ISSN: | 1178-7074 |